Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
Company to Host Conference Call, May 13, 2024 at 4:30 p.m. ET
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare
diseases, will release its financial results for the first quarter ended March 31, 2024, after the market close on Monday, May 13, 2024. Management will then host a webcast and conference call at
4:30 p.m. ET on May 13.
Title: |
Capricor Therapeutics First Quarter 2024 Financial Results and Recent Corporate Update Conference Call and Webcast |
Date: |
Monday, May 13, 2024 |
Time: |
4:30 p.m. ET |
Conference Call Details: |
Toll-Free: 1-888-886-7786 International: 1-416-764-8658 Conference ID: 01529679 Participants can use guest dial-in numbers above and be answered by an operator or click the Call me link for instant telephone access to the event. |
Webcast: |
Webcast Link - Click Here |
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About Capricor Therapeutics
Lesen Sie auch
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, CAP-1002 — an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown CAP-1002 to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. CAP-1002 is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). Capricor is also harnessing the power of our exosome technology, using our proprietary StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.